Ariad Pharmaceuticals Inc. - ARIA- Profile

Ariad Pharmaceuticals Incorporated. The Group's principal activities are the discovery and development of medicines that treat cancer by regulating cell signaling with small molecules. The Group's lead product candidate, AP23573, is in multiple phase 2 and 1b clinical trials and is used for the treatment of solid tumors and hematologic malignancies. In the Group's bone-targeted mTOR inhibitor program, it is developing a novel and potent follow-on product candidate analogous to AP23573, which treats bone cancers and block the spread of bone cancers. In the Group's oncogenic kinase inhibitor program, it is developing potent inhibitors of enzymes involved in the growth, proliferation and spread of cancer. The Group operates only in the United States. Discovers and develops medicines that regulate cell signaling with small molecules